SCANCELL HOLDINGS PLC
A clinical-stage company developing novel immunotherapies for the treatment of cancer.
SCLP | IL
Overview
Corporate Details
- ISIN(s):
- GB00B63D3314 (+2 more)
- LEI:
- 2138008RXEG856SNP666
- Country:
- United Kingdom
- Address:
- BELLHOUSE BUILDING, OX4 4GA OXFORD
- Website:
- https://www.scancell.co.uk/
Description
Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-09 08:15 |
Continued improvement in PFS with iSCIB1+
|
English | 33.0 KB | ||
| 2025-11-07 08:15 |
Research Update
|
English | 17.3 KB | ||
| 2025-10-30 16:30 |
Result of AGM
|
English | 10.9 KB | ||
| 2025-10-03 08:00 |
Notice of AGM
|
English | 12.9 KB | ||
| 2025-09-16 08:00 |
Director Dealing
|
English | 22.4 KB | ||
| 2025-09-11 08:00 |
Final Results
|
English | 232.3 KB | ||
| 2025-09-04 08:00 |
Notice of Results
|
English | 12.8 KB | ||
| 2025-08-08 13:31 |
Director Dealing
|
English | 22.0 KB | ||
| 2025-08-04 11:23 |
Director/PDMR Shareholding
|
English | 22.7 KB | ||
| 2025-07-22 08:00 |
Strong Phase 2 data on iSCIB1+ in Melanoma
|
English | 20.8 KB | ||
| 2025-07-16 08:00 |
Share Option Exercise
|
English | 13.6 KB | ||
| 2025-06-25 08:00 |
Scancell initiates new arm in SCOPE Phase 2 study
|
English | 18.2 KB | ||
| 2025-02-20 08:00 |
Issue of share options
|
English | 41.5 KB | ||
| 2025-02-17 08:00 |
Scancell presenting at AACR IO conference
|
English | 19.6 KB | ||
| 2025-01-30 08:00 |
Interim Results
|
English | 250.6 KB |
Automate Your Workflow. Get a real-time feed of all SCANCELL HOLDINGS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SCANCELL HOLDINGS PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SCANCELL HOLDINGS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
